Evidence map›Paper›PMID 40313720›Full record

ReviewFrontiers in cell and developmental biology2025

Artificial intelligence technology in ophthalmology public health: current applications and future directions.

ShuYuan Chen, Wen Bai

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. [Neurodegeneration and retinal changes-A literature overview].Zeitschrift fur Gerontologie und Geriatrie · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

ShuYuan ChenXuzhou Medical University, Xuzhou, China.
Wen BaiThe Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global eye health has become a critical public health challenge, with the prevalence of blindness and visual impairment expected to rise significantly in the coming decades. Traditional ophthalmic public health systems face numerous obstacles, including the uneven distribution of medical resources, insufficient training for primary healthcare workers, and limited public awareness of eye health. Addressing these challenges requires urgent, innovative solutions. Artificial intelligence (AI) has demonstrated substantial potential in enhancing ophthalmic public health across various domains. AI offers significant improvements in ophthalmic data management, disease screening and monitoring, risk prediction and early warning systems, medical resource allocation, and health education and patient management. These advancements substantially improve the quality and efficiency of healthcare, particularly in preventing and treating prevalent eye conditions such as cataracts, diabetic retinopathy, glaucoma, and myopia. Additionally, telemedicine and mobile applications have expanded access to healthcare services and enhanced the capabilities of primary healthcare providers. However, there are challenges in integrating AI into ophthalmic public health. Key issues include interoperability with electronic health records (EHR), data security and privacy, data quality and bias, algorithm transparency, and ethical and regulatory frameworks. Heterogeneous data formats and the lack of standardized metadata hinder seamless integration, while privacy risks necessitate advanced techniques such as anonymization. Data biases, stemming from racial or geographic disparities, and the "black box" nature of AI models, limit reliability and clinical trust. Ethical issues, such as ensuring accountability for AI-driven decisions and balancing innovation with patient safety, further complicate implementation. The future of ophthalmic public health lies in overcoming these barriers to fully harness the potential of AI, ensuring that advancements in technology translate into tangible benefits for patients worldwide.

Indexed as

artificial intelligencedigital healthophthalmologypublic healthtelemedicine

Identifiers

PMID40313720
PMCPMC12044197

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.